O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-7.79%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.22B
AUM Growth
+$5.22B
(-18%)
Cap. Flow
-$466M
Cap. Flow
% of AUM
-8.93%
Top 10 Holdings %
Top 10 Hldgs %
39.09%
Holding
140
New
13
Increased
17
Reduced
36
Closed
24
Top Buys
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$161M |
| 2 |
Humana
HUM
|
$46.5M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
$45.1M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$41.7M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$32.3M |
Top Sells
| 1 |
Agilent Technologies
A
|
$66.7M |
| 2 |
Bristol-Myers Squibb
BMY
|
$61M |
| 3 |
Boston Scientific
BSX
|
$60.4M |
| 4 |
Merck
MRK
|
$51.9M |
| 5 |
Illumina
ILMN
|
$51.6M |
Sector Composition
| 1 | Healthcare | 98.11% |
| 2 | Financials | 1.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Xtant Medical Holdings
XTNT
$83.3M
| $26.1M | 0.5% | 9,207,012 | – | – |
|
52
IQVIA
IQV
$32.4B
| $26.1M | 0.5% | +175,000 | New | +$26.1M |
|
|
ONCE
53
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $23.8M | 0.45% | 244,900 +25,000 | +11% | +$2.42M |
|
54
Prothena Corp
PRTA
$441M
| $23.7M | 0.45% | 3,022,117 -43,161 | -1% | -$338K |
|
55
Amgen
AMGN
$155B
| $23.6M | 0.45% | 122,100 | – | – |
|
56
Spyre Therapeutics
SYRE
$996M
| $22M | 0.42% | 2,865,524 +700,000 | +32% | +$5.38M |
|
57
Adverum Biotechnologies
ADVM
$64.6M
| $21.9M | 0.42% | 4,012,969 +2,052,769 | +105% | +$11.2M |
|
58
Verrica Pharmaceuticals
VRCA
$52.8M
| $21.8M | 0.41% | 1,479,733 | – | – |
|
|
OBSV
59
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $21.7M | 0.41% | 2,605,531 | – | – |
|
60
CRISPR Therapeutics
CRSP
$4.71B
| $21.2M | 0.4% | +516,400 | New | +$21.2M |
|
61
Krystal Biotech
KRYS
$4.27B
| $20.9M | 0.4% | 601,950 -40,056 | -6% | -$1.39M |
|
62
Gilead Sciences
GILD
$140B
| $20.7M | 0.39% | 326,100 -75,500 | -19% | -$4.79M |
|
63
Alcon
ALC
$39.5B
| $20.5M | 0.39% | 351,380 | – | – |
|
64
Corvus Pharmaceuticals
CRVS
$428M
| $20.4M | 0.39% | 6,767,584 +201,899 | +3% | +$608K |
|
65
scPharmaceuticals
SCPH
$295M
| $20M | 0.38% | 3,409,865 | – | – |
|
66
Aurinia Pharmaceuticals
AUPH
$1.58B
| $18.9M | 0.36% | 3,531,002 | – | – |
|
67
Novo Nordisk
NVO
$251B
| $17.1M | 0.32% | 330,000 | – | – |
|
68
Zai Lab
ZLAB
$3.68B
| $16.6M | 0.32% | 514,000 -655,000 | -56% | -$21.2M |
|
|
SVA
69
DELISTED
Sinovac Biotech, Ltd
SVA
| $16.6M | 0.32% | 2,839,500 | – | – |
|
70
Apellis Pharmaceuticals
APLS
$3.48B
| $15M | 0.29% | 623,859 -1,199,841 | -66% | -$28.9M |
|
|
FOMX
71
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $14.6M | 0.28% | 4,788,896 -406,434 | -8% | -$1.24M |
|
|
ALPN
72
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $14.5M | 0.28% | 3,670,955 | – | – |
|
73
KALA BIO
KALA
$78.8M
| $13.1M | 0.25% | 3,447,840 | – | – |
|
74
Takeda Pharmaceutical
TAK
$47.3B
| $12.9M | 0.24% | 750,000 | – | – |
|
75
X4 Pharmaceuticals
XFOR
$84.2M
| $11.9M | 0.23% | 936,493 | – | – |
|